The global genome editing market revenue was around US$ 7195.9 million in 2022 and is estimated to reach US$ 44,047.7 million by 2031, growing at a compound annual growth rate (CAGR) of 22.3% during the forecast period from 2023 to 2031.
Genome editing is a group of technologies that enables researchers to alter the deoxyribonucleic acid (DNA) of an organism. These technologies allow the removal, addition or alteration of genetic material at exact locations in the genome. Several approaches have been developed for genome editing.
Market Driving Factors
Advancement in genome editing drives market growth. Recent advances in this field have significantly enhanced genome editing capabilities, allowing the transition of interesting gene sequences in various model species and cell types. Additionally, genome engineering has evolved into a potentially game-changing diagnostic instrument for oncology studies. Massive research organizations, such as academic and government research institutions, utilize genome engineering. As a result, the rapid advancement of gene editing technology is the primary factor behind this extreme shift away from academics and toward diagnostic and clinical laboratories.
The surge in application areas of genomics boosts the market. Applications areas for genomics include agribusiness, drug research, forensics, veterinary sciences, and the identification of human genetic abnormalities. The utilization of genomics in forensic studies has dramatically increased, largely due to products provided by Illumina (U.S.), which were designed especially for the field. Fingerprint profiling was previously done using DNA analysis. Next-generation sequencing (NGS) helps with crime scene investigation and allows for the extraction of additional data from damaged or traces of DNA.
The high price of genome editing systems constrains market growth.
Regional Analysis
North America is projected to dominate the market. This is due to the development of gene therapy in the United States, the increase in usage of genetically modified crops, the growth in the prevalence of cancer and infectious diseases, and the availability of research grants and funding are boosting the market in the region.
Asia Pacific dominates the market. In the region, China is the largest market for genome editing technology because the government programs encourage the advancement of genomic research. In addition, the Chinese government's surge in focus on precision medicine and the existence of major players such as Hebei Senlang Biotechnology and BGI. Furthermore, surge in investment in R&D, an increase in the prevalence of genetic diseases, and government initiatives that help genomic research. Therefore, these factors propel the market growth.
Segmentation Insights
Application Insight
The genetic engineering segment dominates the market. This is due to the rapidly increasing field of gene and stem cell therapy. The utilization of CRISPR gene editing in human induced pluripotent stem cells (hiPSCs) related programs has significant implications in stem cell research for the treatment of several diseases.
End User Insight
The biotechnology and pharmaceutical companies segment dominated the market. The existence of an increasing number of research activities for novel therapeutic development is the main factor contributing to revenue generation. Furthermore, global pharmaceutical companies are collaborating with emerging companies to create novel technologies. In addition, the surge in research development efforts for novel treatments is the major factor to drive the market.
Prominent Companies
Segmentation Outline
The global genome editing market segmentation focuses on Application, Technology, End User, and Region.
By Application
By Technology
By End User
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL GENOME EDITING MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: GENOME EDITING MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL GENOME EDITING MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL GENOME EDITING MARKET, BY APPLICATION
5.1 OVERVIEW
5.2 CELL LINE ENGINEERING
5.3 GENETIC ENGINEERING
5.4 DRUG DISCOVERY
5.5 GENE-MODIFIED CELL THERAPY AND DIAGNOSTICS
5.6 OTHERS
6 GLOBAL GENOME EDITING MARKET, BY TECHNOLOGY
6.1 OVERVIEW
6.2 CRISPR
6.3 TALEN
6.4 ZFN
6.5 OTHERS
7 GLOBAL GENOME EDITING MARKET, BY END USER
7.1 OVERVIEW
7.2 ACADEMICS & GOVERNMENT INSTITUTES
7.3 BIOTECHNOLOGY & PHARMA COMPANIES
7.4 CONTRACT RESEARCH ORGANIZATIONS
8 GLOBAL GENOME EDITING MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO
8.3 EUROPE
8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3.1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA
8.6 SOUTH AMERICA
8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA
9 GLOBAL GENOME EDITING MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
9.4 COMPETITIVE DASHBOARD
9.5 PRODUCT MAPPING
9.6 TOP PLAYER POSITIONING, 2022
9.7 COMPETITIVE HEATMAP
9.8 TOP WINNING STRATEGIES
10 COMPANY PROFILES
10.1 EDITAS MEDICINE INC
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS
10.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.2 AGLIENT TECHNOLOGIES INC
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.3 CRISPR THERAPEUTICS AG
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.4 LONZA GROUP LTD
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.5 THERMO FISHER SCIENTIFIC INC
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.6 GENSCRIPT BIOTECH CORPORATION
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.7 PERKINELMER INC
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.8 DANAHER CORPORATION
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.9 EUROFINS SCIENTIFIC
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.10 MERCK KGAA
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved